کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
4211350 1280636 2011 8 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی پزشکی ریوی و تنفسی
پیش نمایش صفحه اول مقاله
Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD
چکیده انگلیسی

SummaryBackgroundStatic and dynamic lung hyperinflation are associated with exercise impairment and poor outcomes in COPD patients. Aclidinium bromide is a novel, long-acting inhaled muscarinic antagonist currently in development for COPD treatment.MethodsPatients with moderate to severe COPD (N = 181) were randomized to once-daily aclidinium 200 μg or placebo for 6 weeks. Constant work rate cycling exercises at 75% of peak work rate were performed at baseline, Day 1, Week 3, and Week 6. The primary efficacy measure was change in exercise endurance time (ET) from baseline to Week 6. Secondary outcomes included changes in trough forced expiratory volume in 1 s (FEV1), inspiratory capacity (IC), IC/total lung capacity (TLC), and functional residual capacity (FRC) from baseline to Day 1, Week 3, and Week 6. Borg dyspnea scores during exercise, locus of symptom limitation, and safety measures were assessed.ResultsAclidinium significantly improved ET on Day 1 (P = 0.0002), and improvements were sustained through Week 3 (P = 0.0007) and Week 6 (P = 0.0042) vs placebo. Compared with placebo, aclidinium improved trough FEV1, IC, and IC/TLC at Weeks 3 and 6 (P < 0.05 for all). Exertional dyspnea scores at isotime were reduced on Day 1, Week 3, and Week 6 for aclidinium vs placebo (P < 0.05). Furthermore, the likelihood of stopping exercise due to breathing discomfort was lower in the aclidinium group at study end (P = 0.0208) compared with placebo. No differences in safety outcomes were reported between treatments.ConclusionsAclidinium significantly increased exercise tolerance, improved airflow obstruction and lung hyperinflation, and was safe and well tolerated.Registration of TrialThis trial was registered with ClinicalTrials.gov (NCT00500318) under the name “A Study of Exercise Endurance and Lung Hyperinflation in Patients with Moderate to Severe COPD”.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Respiratory Medicine - Volume 105, Issue 4, April 2011, Pages 580–587
نویسندگان
, , , , , , ,